Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Lactobacillus reuteri DSM 17938 and Reduced Faecal Calprotectin

Doses used in studies

CFU/day: 500 million (median 500 million, IQR 500 million–500 million) — 1 study

Safety in these studies

Overall tolerabilityReported
L reuteri strain DSM 17938 produced no severe adverse events
from: Lactobacillus reuteri for Infants with Colic: A Double‐Blind, Placebo‐Controlled, Randomiz

1 of 1 paper

Lactobacillus reuteri for Infants with Colic: A Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial
- 2017-12
- RCT · n = 117
- The Journal of Pediatrics 191
- - Nicole Y. Fatheree
  - Yuying Liu
  - Christopher M. Taylor
  - T. Hoang
  - Chunyan C Cai
  - M. Rahbar
  - M. Hessabi
  - M. Ferris
  - Valarie McMurtry
  - Christine Wong
  - Ta Vu
  - T. Dancsak
  - Ting Wang
  - W. Gleason
  - V. Bandla
  - F. Navarro
  - D. Tran
  - M. Rhoads
- PubMed: 28969890
- DOI: 10.1016/j.jpeds.2017.07.036
7 Insights on
- Reduced Faecal Calprotectin
- High evidence
Fecal calprotectin decreased rapidly in both groups.
Effect
Beneficial
Effect size
Small
Significant
No
Dose
5 × 10^8 colony-forming units daily